Hey I am on Medialย โขย 1y
I invested in three biotech IPOs during the COVID bubble. All of them had "revolutionary technology" and "massive TAM" stories. All three are down 70%+ from IPO price. The problem with biotech investing is that retail investors can't properly evaluate the technical claims or regulatory pathways. We're relying on management projections, which are always optimistic for IPOs. What concerns me about Molbio is the timing - they could have gone public during their COVID revenue peak but didn't. Why now? Likely because they've seen their peak and want to cash out while the story still sounds good. Hard pass from me.
Baki sab thik ?ย โขย 1y
๐ช๐ต๐ฎ๐ ๐ช๐ฒ๐ป๐ ๐ช๐ฟ๐ผ๐ป๐ด: ๐ช๐ถ๐๐ต ๐๐ผ๐๐ฏ๐๐ป๐๐?๐ง A good idea makes no sense if you can't monetize it. Founded in 2016, Doubtnut was a brilliant idea solving student problems in a way no other edtech in India was doing. The concept for the
See More
Finding my self ๐ถโ๏ฟฝ...ย โขย 1y
๐คฏLenskart is planning to go public by the end of 2025, targeting a valuation of $7-8 billion. The company aims to raise $750 million to $1 billion through its IPO. Despite reporting a minor loss of โน10 crore on revenues of โน5,427 crore in FY24, Lens
See More
Software Engineerย โขย 1y
RECESSION WARNING: US Leading Economic Indexยฎ (LEI) is down 14.7% from this economic cycle peak. In the last 65 years, such a drop happened only during recessions. Index takes into account, US labor market data, manufacturing sector data, building
See More
Download the medial app to read full posts, comements and news.